Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Personalis is well-positioned for future growth, driven by its strong financial position, expanding product offerings, and successful partnerships with pharmaceutical companies. With Medicare coverage for their breast cancer tests and ongoing studies showing positive results, the company has potential for increased revenue through biopharmaceutical services and clinical diagnostics. Additionally, their focus on personalized cancer vaccines has attracted a large investment from Merck and has the potential for FDA approval in the future.

Bears say

Personalis is facing potential risks and challenges in its oncology-focused business, including competition from other genomic sequencing companies and uncertainties in reimbursement and pricing. Despite reporting successful clinical trial results for its products, the company may struggle to achieve profitability in the short-term due to limited reimbursement coverage and the need for further investments in research and development. Additionally, the company's financials may also be impacted by fluctuations in its stock price as it continues to use its ATM to raise cash, potentially diluting shareholder value.

Personalis Inc (PSNL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.